If cardiovascular health is what you think is important for deciding between these drug classes, I think our most recent study provides some strong evidence
A higher research reference point
Some experts, like Dr Vanita Rahman, clinic director at Physicians Committee for Responsible Medicine (PCRM) a global not-for-profit that promotes plant-based nutrition underlined that long-term safety data for these medicines is very limited yet
When your results depend on molecular precision, you can't afford to gamble on your source material
Steven Dayan, MD, is a plastic surgeon in Chicago
Policy changes like the Inflation Reduction Acts $2,000 out-of-pocket (OOP) cap for Medicare Part D beneficiaries may offer some relief, as patients who reach the cap pay $0 thereafter, but they also risk prompting payers to tighten coverage for high-cost drugs, especially those indicated for obesity